Compare Crispr Therapeutics AG (CRSP) vs Kaltura Inc (KLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Kaltura Inc — how do they compare? Crispr Therapeutics AG trades at $51.44 (market cap $4.88B), while Kaltura Inc trades at $1.32 (market cap $199.08M). The key difference: Crispr Therapeutics AG is far larger — about 24.5× Kaltura Inc's market cap, and Kaltura Inc is more actively traded (175,927 versus 2,861,747). Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Kaltura Inc for 21 Days on average.
| CRSP | KLTR | |
|---|---|---|
Market Cap | $4.88B | $199.08M |
Volume | 2,861,747 | 175,927 |
Sector | Health | Technology |
52-Week High | $74.92 | $1.89 |
52-Week Low | $44.34 | $1.08 |
Typical Hold Time | 77 Days | 21 Days |
Enterprise Value | $3.30B | $211.29M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% on the day, with a bearish technical signal and negative profitability metrics. The company reported no revenue in 2025 with a net loss of $581.60M, though recent earnings beat expectations in Q2 2026. Analyst sentiment remains positive with a $67.83 price target and 57.9% buy ratings, supported by upcoming clinical data catalysts for its gene-editing therapies.
The stock faces significant fundamental challenges with negative margins and cash burn, but strong analyst support and pipeline progress offer long-term potential. Key risks include clinical trial outcomes and commercialization execution, while institutional interest and positive media coverage provide near-term catalysts for investor consideration.
KLTR trades at $1.33, up 3.91% today, showing positive momentum despite a bearish technical signal. The company demonstrates improving fundamentals with revenue stabilizing around $181M and net losses narrowing from -$68M in 2022 to -$12M in 2025. Recent earnings beats and industry recognition for AI-powered video platforms provide optimism, though negative ROE (-134.25%) and high debt levels remain concerns.
KLTR presents a turnaround story with improving financials and strong AI positioning, but faces significant execution risks. The stock offers speculative upside if the company can achieve profitability, though current valuation metrics (P/S 1.08, EV/EBITDA 271.59) reflect market skepticism about near-term earnings potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
